ENG and neoplasm: Interestingly, in contrast to tumor endothelium, the CD105+ cells were resistant to the VEGF-A inhibitor Bevacizumab, underscoring that CD105+ stem-like cells are not identical to GBM endothelial cells (Fig. 6B, Additional file 3: Fig S6B).